Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

VYNDAQEL

TAFAMIDIS MEGLUMINE

Standard Dose
20MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview VYNDAQEL is listed in Drugs@FDA under application 211996 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient TAFAMIDIS MEGLUMINE Form and strength CAPSULE;ORAL - 20MG Sponsor FOLDRX PHARMS Submission history Latest submission status date: 2023-10-17 00:00:00.

Structured Monograph

Clinical summary

Approval overview VYNDAQEL is listed in Drugs@FDA under application 211996 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient TAFAMIDIS MEGLUMINE Form and strength CAPSULE;ORAL - 20MG Sponsor FOLDRX PHARMS Submission history Latest submission status date: 2023-10-17 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.